

# Vincenzo Solfrizzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6474467/publications.pdf>

Version: 2024-02-01

123  
papers

12,098  
citations

50244

46  
h-index

30058

103  
g-index

125  
all docs

125  
docs citations

125  
times ranked

16744  
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	1.7	3
2	Frailty and outcome after traumatic brain injury. <i>Lancet Neurology</i> , The, 2022, 21, 107-108.	4.9	6
3	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210816.	1.1	8
4	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
5	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. <i>GeroScience</i> , 2022, 44, 1373-1392.	2.1	36
6	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
7	Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience. <i>Open Medicine (Poland)</i> , 2022, 17, 1203-1215.	0.6	5
8	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	1.9	6
9	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. <i>GeroScience</i> , 2021, 43, 1003-1014.	2.1	6
10	Carotenoids and Cognitive Outcomes: A Meta-Analysis of Randomized Intervention Trials. <i>Antioxidants</i> , 2021, 10, 223.	2.2	37
11	Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®). <i>Pharmaceuticals</i> , 2021, 14, 305.	1.7	23
12	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 561.	1.2	31
13	COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1-7.	1.0	11
14	Associations between nutritional frailty and 8-year all-cause mortality in older adults: The Salus in Apulia Study. <i>Journal of Internal Medicine</i> , 2021, 290, 1071-1082.	2.7	31
15	Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 853-857.	1.0	14
16	Anti-amyloid- $\beta$ protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	1.0	57
17	Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty. <i>Ageing Research Reviews</i> , 2020, 64, 101148.	5.0	43
18	Agreement of a Short Form of the Self-Administered Multidimensional Prognostic Index (SELFY-MPI-SF): A Useful Tool for the Self-Assessment of Frailty in Community-Dwelling Older People. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 493-499.	1.3	11

#	ARTICLE	IF	CITATIONS
19	The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	0.8	4
20	Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. <i>Lancet</i> , 2019, 394, 639-651.	6.3	325
21	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.4	47
22	Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 87.	1.2	29
23	Time to test antibacterial therapy in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2905-2929.	3.7	89
24	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates APOE, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
25	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4333-4344.	1.9	19
26	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 699-711.	1.2	17
27	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	1.2	214
28	Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	0.9	43
29	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. <i>Rejuvenation Research</i> , 2018, 21, 3-14.	0.9	25
30	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
31	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	1.4	66
32	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 480-498.	2.9	27
33	Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: a systematic review and meta-analysis of individual participant data. <i>Clinical Epidemiology</i> , 2018, Volume 10, 363-379.	1.5	49
34	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S229-S254.	1.2	38
35	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Association</i> , 2017, 318, 89.e1-89.e8.	1.2	126
36	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	1.2	249

#	ARTICLE	IF	CITATIONS
37	Cognitive frailty: a potential target for secondary prevention of dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1023-1027.	1.5	40
38	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	1.3	36
39	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
40	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. American Journal of Geriatric Psychiatry, 2017, 25, 1236-1248.	0.6	90
41	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-15.	0.9	138
42	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. International Psychogeriatrics, 2016, 28, 1111-1124.	0.6	19
43	Emerging drugs to reduce abnormal $\beta$ -amyloid protein in Alzheimer's disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	1.0	54
44	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. Immunotherapy, 2016, 8, 1119-1134.	1.0	61
45	Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials. Frontiers of Neurology and Neuroscience, 2016, 39, 124-135.	3.0	4
46	Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study. Journal of Alzheimer's Disease, 2016, 53, 505-515.	1.2	27
47	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 843-846.	1.5	10
48	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	1.4	35
49	Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?. Expert Opinion on Pharmacotherapy, 2016, 17, 457-461.	0.9	17
50	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. Journal of Alzheimer's Disease, 2015, 47, 793-813.	1.2	108
51	Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. Journal of Alzheimer's Disease, 2015, 47, 889-899.	1.2	51
52	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. Frontiers in Aging Neuroscience, 2015, 7, 113.	1.7	67
53	Postural and Balance Disorders in Patients with Parkinson's Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment. Parkinson's Disease, 2015, 2015, 1-7.	0.6	11
54	Epidemiology of age related hearing loss: A review. Hearing, Balance and Communication, 2015, 13, 77-81.	0.1	20

#	ARTICLE	IF	CITATIONS
55	Age-related hearing impairmentâ€™ a risk factor and frailty marker for dementia and AD. <i>Nature Reviews Neurology</i> , 2015, 11, 166-175.	4.9	192
56	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. <i>Rejuvenation Research</i> , 2015, 18, 389-412.	0.9	112
57	Progresses in treating agitation: a major clinical challenge in Alzheimerâ€™s disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2581-2588.	0.9	43
58	Nutrition, frailty, and Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 221.	1.7	16
59	Efficacy and safety studies of gantenerumab in patients with Alzheimerâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 973-986.	1.4	42
60	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	1.3	86
61	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <i>Current Opinion in Psychiatry</i> , 2014, 27, 128-137.	3.1	86
62	The Prevalence of Peripheral and Central Hearing Impairment and Its Relation to Cognition in Older Adults. <i>Audiology and Neuro-Otology</i> , 2014, 19, 10-14.	0.6	102
63	Amyloid-directed monoclonal antibodies for the treatment of Alzheimerâ€™s disease: the point of no return?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1465-1476.	1.4	63
64	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. <i>Current Nutrition Reports</i> , 2014, 3, 110-129.	2.1	9
65	Plant-Based Nutraceutical Interventions against Cognitive Impairment and Dementia: Meta-Analytic Evidence of Efficacy of a Standardized Ginkgo biloba Extract. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 605-611.	1.2	28
66	Mediterranean Diet and Cognitive Decline. A Lesson from the Whole-Diet Approach: What Challenges Lie Ahead?. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 283-286.	1.2	48
67	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	1.1	155
68	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. <i>The Italian Longitudinal Study on Aging. Age</i> , 2013, 35, 441-453.	3.0	35
69	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013, 9, 113-122.	0.4	140
70	Neuropsychiatric Symptoms and Functional Status in Alzheimerâ€™s Disease and Vascular Dementia Patients. <i>Current Alzheimer Research</i> , 2012, 9, 759-771.	0.7	75
71	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimerâ€™s disease patients. <i>Future Neurology</i> , 2012, 7, 395-401.	0.9	1
72	Advances in the identification of $\beta$ -secretase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 19-37.	2.5	45

#	ARTICLE	IF	CITATIONS
73	Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S31-S75.	1.2	44
74	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1218-1238.	1.3	90
75	Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. <i>Age</i> , 2012, 34, 507-517.	3.0	51
76	Monoclonal antibodies against $\beta$ -amyloid ( $A\beta$ ) for the treatment of Alzheimer's disease: the $A\beta$ target at a crossroads. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 679-686.	1.4	40
77	Diet and Alzheimer's disease risk factors or prevention: the current evidence. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 677-708.	1.4	231
78	Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. <i>Neurobiology of Aging</i> , 2011, 32, 1932-1941.	1.5	108
79	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	1.1	18
80	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708
81	The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1062-1070.	1.3	27
82	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 691-724.	1.2	139
83	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 17-30.	1.2	78
84	Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 715-740.	1.2	149
85	Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1179-1183.	1.2	6
86	Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 139-141.	1.8	18
87	Apolipoprotein E-related all-cause mortality in hospitalized elderly patients. <i>Age</i> , 2010, 32, 411-420.	3.0	5
88	EFFECT OF DONEPEZIL ON THE CONTINUUM OF DEPRESSIVE SYMPTOMS, MILD COGNITIVE IMPAIRMENT, AND PROGRESSION TO DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 389-390.	1.3	6
89	PLASMA LEVELS OF $\omega$ 3 POLYUNSATURATED FATTY ACIDS AND COGNITIVE DECLINE: POSSIBLE ROLE OF DEPRESSIVE SYMPTOMS AND APOLIPOPROTEIN E GENOTYPING. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2249-2251.	1.3	4
90	PLASMA LIPID DISTURBANCES AND COGNITIVE DECLINE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2429-2430.	1.3	20

#	ARTICLE	IF	CITATIONS
91	Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 424-431.	0.7	6
92	Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: A case report. <i>Journal of Rehabilitation Medicine</i> , 2010, 42, 891-894.	0.8	12
93	Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke. <i>Brain Injury</i> , 2010, 24, 1108-1112.	0.6	12
94	Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 433-440.	0.9	100
95	Bapineuzumab: anti- $\beta$ -amyloid monoclonal antibodies for the treatment of Alzheimer's disease. <i>Immunotherapy</i> , 2010, 2, 767-782.	1.0	52
96	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 98-116.	0.6	502
97	Polymorphisms in Glutathione S-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. <i>Rejuvenation Research</i> , 2010, 13, 645-652.	0.9	23
98	Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report. <i>Journal of Chiropractic Medicine</i> , 2010, 9, 132-137.	0.3	13
99	Interleukin 6's 174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 177-182.	2.5	27
100	Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. <i>Ageing Research Reviews</i> , 2010, 9, 184-199.	5.0	112
101	REVIEW: $\beta$ -Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 272-284.	1.9	63
102	Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian Project on Epidemiology of Alzheimer's disease (IPREA). <i>Ageing Clinical and Experimental Research</i> , 2010, 22, 440-449.	1.4	22
103	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. <i>Scientific World Journal, The</i> , 2009, 9, 373-389.	0.8	24
104	Dietary Fatty Acids and Predementia Syndromes. <i>Scientific World Journal, The</i> , 2009, 9, 792-810.	0.8	10
105	All-Cause Mortality and Competing Risks of Fatal and Nonfatal Vascular Events in the Italian Longitudinal Study on Aging: Impact of Lipoprotein(a). <i>Rejuvenation Research</i> , 2009, 12, 395-402.	0.9	4
106	POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENT "NO DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 943-944.	1.3	3
107	Whole-Diet Approach: Working on a Criterion Validity for Age-Related Cognitive Decline and Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1944-1946.	1.3	13
108	Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. <i>Ageing Research Reviews</i> , 2009, 8, 214-236.	5.0	46

#	ARTICLE	IF	CITATIONS
109	Acoustic analysis of swallowing sounds: A new technique for assessing dysphagia. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 639-645.	0.8	58
110	Botulinum Toxin Type A in the Treatment of Focal Hand Dystonia After Surgical Treatment for Thumb Duplication. <i>Orthopedics</i> , 2009, 32, 529.	0.5	2
111	Botulinum Toxin Type A in the Treatment of Painful Adductor Muscle Contracture After Total Hip Arthroplasty. <i>Orthopedics</i> , 2009, 32, .	0.5	8
112	Lifestyle-related factors in predementia and dementia syndromes. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 133-158.	1.4	129
113	Incident Occurrence of Depressive Symptoms among Patients with Mild Cognitive Impairment â€” The Italian Longitudinal Study on Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 55-64.	0.7	66
114	Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2006, 188, 455-461.	0.4	42
115	Circulating biomarkers of cognitive decline and dementia. <i>Clinica Chimica Acta</i> , 2006, 364, 91-112.	0.5	124
116	Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5-year follow-up of the Italian Longitudinal Study on Aging. <i>Neurobiology of Aging</i> , 2006, 27, 1694-1704.	1.5	222
117	Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 303-330.	1.2	44
118	Role of Olive Oil and Monounsaturated Fatty Acids in Mitochondrial Oxidative Stress and Aging. <i>Nutrition Reviews</i> , 2006, 64, S31-S39.	2.6	15
119	Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Experimental Gerontology</i> , 2006, 41, 619-627.	1.2	75
120	Dietary fatty acids intake: possible role in cognitive decline and dementia. <i>Experimental Gerontology</i> , 2005, 40, 257-270.	1.2	113
121	Unsaturated fatty acids intake and all-causes mortality: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. <i>Experimental Gerontology</i> , 2005, 40, 335-343.	1.2	33
122	Selective Attention Skills in Differentiating between Alzheimer's Disease and Normal Aging. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 99-109.	1.2	24
123	Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients â‰¥65 years of age (The Italian Longitudinal Study on Aging). <i>American Journal of Cardiology</i> , 2002, 89, 825-829.	0.7	37